牛牛AI助理已提取核心訊息
On January 26, 2024, Evelo Biosciences, Inc. held a special meeting of stockholders where two key proposals were voted upon. The first proposal, which passed with 11,168,514 votes for, 222,299 against, and 7,940 abstained, was the approval of the liquidation and dissolution of the company and the Plan of Liquidation and Dissolution. The second proposal, which also passed, granted discretionary authority to adjourn the special meeting to solicit additional proxies if necessary. However, adjournment was not required as the first proposal received sufficient votes for approval. The Board of Directors now has the authority to proceed with the dissolution but retains the discretion to decide the timing and whether to move forward with or abandon the dissolution, or to amend the plan as permitted by Delaware law without further stockholder approval. This follows the delisting of Evelo Biosciences' shares from Nasdaq, as reported in a previous Form 8-K filed on November 21, 2023.
On January 26, 2024, Evelo Biosciences, Inc. held a special meeting of stockholders where two key proposals were voted upon. The first proposal, which passed with 11,168,514 votes for, 222,299 against, and 7,940 abstained, was the approval of the liquidation and dissolution of the company and the Plan of Liquidation and Dissolution. The second proposal, which also passed, granted discretionary authority to adjourn the special meeting to solicit additional proxies if necessary. However, adjournment was not required as the first proposal received sufficient votes for approval. The Board of Directors now has the authority to proceed with the dissolution but retains the discretion to decide the timing and whether to move forward with or abandon the dissolution, or to amend the plan as permitted by Delaware law without further stockholder approval. This follows the delisting of Evelo Biosciences' shares from Nasdaq, as reported in a previous Form 8-K filed on November 21, 2023.
2024年1月26日，Evelo Biosciences, Inc.舉行了一次股東特別會議，對兩項關鍵提案進行了表決。第一項提案以11,168,514票贊成、222,299票反對、7,940票棄權獲得通過，是批准公司的清算和解散以及清算和解散計劃。第二項提案也獲得通過，授權酌情宣佈特別會議休會，以便在必要時徵集更多代理人。但是，由於第一項提案獲得了足夠的票數可供批准，因此不需要休會。董事會現在有權着手解散，但保留決定時機以及推進還是放棄解散的自由裁量權，或者在未經股東進一步批准的情況下根據特拉華州法律允許修改計劃的自由裁量權。在此之前，正如2023年11月21日提交的8-K表格所報告的那樣，Evelo Biosciences的股票已從納斯達克退市。
2024年1月26日，Evelo Biosciences, Inc.舉行了一次股東特別會議，對兩項關鍵提案進行了表決。第一項提案以11,168,514票贊成、222,299票反對、7,940票棄權獲得通過，是批准公司的清算和解散以及清算和解散計劃。第二項提案也獲得通過，授權酌情宣佈特別會議休會，以便在必要時徵集更多代理人。但是，由於第一項提案獲得了足夠的票數可供批准，因此不需要休會。董事會現在有權着手解散，但保留決定時機以及推進還是放棄解散的自由裁量權，或者在未經股東進一步批准的情況下根據特拉華州法律允許修改計劃的自由裁量權。在此之前，正如2023年11月21日提交的8-K表格所報告的那樣，Evelo Biosciences的股票已從納斯達克退市。
有用
沒用